| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/09/2001 | US6300364 For decreasing low density lipoprotein cholesterol level |
| 10/09/2001 | US6300363 Indole compounds as COX-2 inhibitors |
| 10/09/2001 | US6300360 For therapy of stress related disorders such as post traumatic stress disorder (ptsd) as well as depression, headache and anxiety |
| 10/09/2001 | US6300359 (E)-3-[1-n-Butyl-5-[2-(2-carboxyphenyl)methoxy-4-chlorophenyl]-1H-pyrazol-4-yl]-2-[(5-methoxy-2,3-dihydrobenzofuran-6-yl)methyl]-prop-2-enoic acid monoargininyl salt |
| 10/09/2001 | US6300358 Administering benzydamine or a physiologically acceptable acid addition salt for therapy of condition caused by tumor necrosis factor |
| 10/09/2001 | US6300357 For therapy of mycotic disease of a human being and an animal |
| 10/09/2001 | US6300356 Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist |
| 10/09/2001 | US6300355 For therapy of cancer |
| 10/09/2001 | US6300354 For therapy of neuroleptic diseases |
| 10/09/2001 | US6300352 For therapy of asthma |
| 10/09/2001 | US6300351 For inhibiting human immunodeficiency virus-1 (hiv-1) reverse transcriptase |
| 10/09/2001 | US6300350 Administering to mammal an retinoic acid (rar) agonist that is at least gamma selective and is rar.alpha. sparing for treating emphysema |
| 10/09/2001 | US6300349 Inhibition of tumor necrosis factor alpha |
| 10/09/2001 | US6300347 For therapy of tumor necrosis factor and interleukin-1 mediated diseases such as rheumatoid arthritis and diseases of bone metabolism, e.g. osteoporosis |
| 10/09/2001 | US6300346 Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions |
| 10/09/2001 | US6300345 Cyanoguanidines as cell proliferation inhibitors |
| 10/09/2001 | US6300344 Heterocyclic compounds |
| 10/09/2001 | US6300343 Promoting smoking cessation or reduction or preventing relapse smoking by administering of paroxetine or a pharmaceutically acceptable salt or solvate |
| 10/09/2001 | US6300342 Antithrombotic phenylalkyl derivatives |
| 10/09/2001 | US6300341 2-substituted heterocyclic sulfonamides |
| 10/09/2001 | US6300340 Useful for therapy of cancer and solid tumors |
| 10/09/2001 | US6300339 Compounds, their preparation and use |
| 10/09/2001 | US6300338 Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| 10/09/2001 | US6300336 Method of treating or inhibiting functional disturbances or illnesses of the lower intestinal tracts, particularly abdominal visceral pain which accompanies them |
| 10/09/2001 | US6300335 Urogenital disorders |
| 10/09/2001 | US6300334 Thieno[2,3-d]pyrimidine-2,4-diones |
| 10/09/2001 | US6300332 Methods for reducing respiratory depression and attendant side effects of mu opioid compounds |
| 10/09/2001 | US6300330 Blood coagulation factor x inhibitors as anticoagulants |
| 10/09/2001 | US6300329 Heterocyclic pyrido(1,2-a)pyrazine compounds for treatment of parkinson's disease |
| 10/09/2001 | US6300328 Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage |
| 10/09/2001 | US6300327 Neurotropin inhibitors |
| 10/09/2001 | US6300326 Composition and method for control and treatment of cutaneous inflammation |
| 10/09/2001 | US6300325 Heterocyclic receptor antagonist |
| 10/09/2001 | US6300318 Antibacterial and antibiotic methods using peptide nucleic acids and pharmaceutical compositions therefor |
| 10/09/2001 | US6300317 Eukarotic cells, polynucleotide, functional agents, membrane permeability, subcellar localization agents and polynucleotide masking agents |
| 10/09/2001 | US6300316 C-4 substituted macrolide antibiotics |
| 10/09/2001 | US6300314 Admnistering heterocyclic peptides to stimulate hematopoiesis of cells |
| 10/09/2001 | US6300313 Means for treating prostate hypertrophy and prostate cancer |
| 10/09/2001 | US6300127 Bone mineralization proteins, DNA, vectors, expression systems |
| 10/09/2001 | US6300097 A polypeptide; therapy and diagnosis of bacterial infections; upper respiratory infections, toxic shock syndrome, septic arthritis and intestinal disorders |
| 10/09/2001 | US6300057 Melanins with improved ability to inhibit HIV replication |
| 10/09/2001 | US6299906 Process for making submicron particles |
| 10/09/2001 | US6299904 Capable of buccal disintegration or dissolution |
| 10/09/2001 | US6299903 Delayed release pharmaceutical formulation containing a β-lactam antibiotic |
| 10/09/2001 | US6299902 Absorption |
| 10/09/2001 | US6299901 Administering r(-)desmethylselegiline using dosage regimen to treat one or more wthdrawal symptoms associated with one or more drugs selected from addictive psychostimulants, opiates, narcotics, barbiturates, alcohol, and nicotine |
| 10/09/2001 | US6299900 Non-occlusive, percutaneous or transdermal drug delivery system |
| 10/09/2001 | US6299897 Attaching selectin binding carbohydrate to a cross-linkable lipid; attaching an acidic group to a cross linkable lipid; forming lipids into sheet; crosslinking lipids |
| 10/09/2001 | US6299889 Stable ascorbic acid preparation for topical use |
| 10/09/2001 | US6299888 Azelastine hydrochloride-containing percutaneous preparation having good percutaneous absorbability and reduced skin irritation |
| 10/09/2001 | US6299878 Immunosuppressing mammal; administering pooled transferrin-derived glycans from mammal which are free of transferrin polypeptide moieties; grafting foreign cells or tissues to controll immune response |
| 10/09/2001 | US6299876 Cytotoxic drug therapy |
| 10/09/2001 | US6299872 Administering combination of interferon alpha and ribavirin to reduce symptoms of hepatitis c infection |
| 10/09/2001 | US6299868 Fat-binding polymers |
| 10/09/2001 | US6299867 Adsorbent |
| 10/09/2001 | US6299865 Selecting area of skin; applying alkaline phosphatase inhibitor other than cromoglycate or its salt to reduce hair growth |
| 10/09/2001 | US6299861 Administering aerosol of inhalable ipratropium bromide for inhibiting acetylcholine induced bronchospasm in humans |
| 10/09/2001 | CA2325541C Extended release formulations of erythromycin derivatives |
| 10/09/2001 | CA2235025C Bone morphogenetic protein and fibroblast growth factor compositions and methods for the induction of cardiogenesis |
| 10/09/2001 | CA2222296C Peptide and method of obtaining it |
| 10/09/2001 | CA2218306C Method of preventing allograft rejection |
| 10/09/2001 | CA2215923C A method of treatment of mania and bipolar disorder |
| 10/09/2001 | CA2203513C Liposome composition containing selegilin |
| 10/09/2001 | CA2202057C 5-lipoxygenase inhibitors |
| 10/09/2001 | CA2195844C Semi-synthetic taxanes with anti-tumoural activity |
| 10/09/2001 | CA2161297C Novel diosmetin derivatives; process for preparing the same and pharmaceutical_compositions containing them |
| 10/09/2001 | CA2142320C Sustained release tablets containing bupropion |
| 10/09/2001 | CA2123223C Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor |
| 10/09/2001 | CA2119662C New nitrogen bicyclic derivatives, their preparation process and pharmaceutical compositions comtaining them |
| 10/09/2001 | CA2095354C Method and composition for controlled delivery of biologically active agents |
| 10/09/2001 | CA2082825C Inhibition of viral infection |
| 10/09/2001 | CA2029787C Method for preparation of taxol using an oxazinone |
| 10/09/2001 | CA2016501C Substituted pyrrole compounds and their applications in pharmacy |
| 10/09/2001 | CA1341304C Pharmaceutical composition for the prevention of sexually transmitted diseases |
| 10/07/2001 | CA2340936A1 Inhibitors for the formation of soluble human cd23 |
| 10/07/2001 | CA2304906A1 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia |
| 10/07/2001 | CA2304869A1 Method of medical treatment using uric acid or precursors thereof |
| 10/06/2001 | CA2343259A1 A process for producing solid creatine dosage forms and dosage forms obtainable thereby |
| 10/05/2001 | CA2303481A1 Pharmaceutical compositions comprising moexipril magnesium |
| 10/04/2001 | WO2001073439A1 Docosahexaenoic acid as retinoid x receptor and uses thereof |
| 10/04/2001 | WO2001073435A1 Methods for detecting inflammation and inflammatory conditions |
| 10/04/2001 | WO2001073150A1 Scaffold-organized clusters and electronic devices made using such clusters |
| 10/04/2001 | WO2001073133A1 Compositions and methods for identifying and targeting cancer cells |
| 10/04/2001 | WO2001073132A1 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| 10/04/2001 | WO2001073131A1 High specificity marker detection |
| 10/04/2001 | WO2001073104A1 Beta-glucans from filamentous fungi |
| 10/04/2001 | WO2001073078A1 A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus orf2, and an antigenic polypeptide |
| 10/04/2001 | WO2001073077A2 Regulation of human serine racemase enzyme |
| 10/04/2001 | WO2001073034A2 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 10/04/2001 | WO2001073033A2 Anti-angiogenic and anti-tumor properties of matin and other laminin domains |
| 10/04/2001 | WO2001073032A2 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 10/04/2001 | WO2001073003A1 Compound, composition and method for the treatment of inflammatory and inflammatory-related disorders |
| 10/04/2001 | WO2001073002A2 Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
| 10/04/2001 | WO2001072960A2 Il-8 receptor antagonists |
| 10/04/2001 | WO2001072849A1 Per(3,6-anhydro)cyclodextrin derivatives, preparation and use thereof for separating ions |
| 10/04/2001 | WO2001072848A1 Glycosaminoglycans derived from the k5 polysaccharide having high anticoagulant and antithrombotic activity and process for their preparation |
| 10/04/2001 | WO2001072846A2 Ligands directed to the non-secretory component, non-stalk region of pigr and methods of use thereof |
| 10/04/2001 | WO2001072837A2 Methods of modulating drug clearance mechanisms by altering sxr activity |
| 10/04/2001 | WO2001072822A2 Genes involved in intestinal inflammatory diseases and use thereof |
| 10/04/2001 | WO2001072779A1 Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto |